NASDAQ: TLSITrisalus Life Sciences Inc Stock
$4.99+0.01 (+0.2%)
Updated Sep 10, 2024
TLSI Price
$4.99
Fair Value Price
N/A
Market Cap
$146.26M
52 Week Low
$3.32
52 Week High
$10.42
P/E
-2.51x
P/B
-6.06x
P/S
5.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.74M
Earnings
-$54.35M
Gross Margin
87.7%
Operating Margin
-216.08%
Profit Margin
-219.7%
Debt to Equity
-2.34
Operating Cash Flow
-$55M
Beta
0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLSI Overview
MedTech Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the healthcare sector in the U.S. MedTech Acquisition was incorporated in 2020 and is headquartered in Greenwich, CT.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLSI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TLSI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TLSI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TLSI due diligence checks available for Premium users.
Be the first to know about important TLSI news, forecast changes, insider trades & much more!
TLSI News
Valuation
TLSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.51x
Industry
42.62x
Market
23.55x
TLSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.06x
Industry
4.08x
TLSI's financial health
Profit margin
Revenue
$7.4M
Net Income
-$4.3M
Profit Margin
-58.8%
TLSI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TLSI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.4M
Liabilities
$56.6M
Debt to equity
-2.34
TLSI's short-term assets ($27.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLSI's long-term liabilities ($44.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.4M
Investing
-$60.0k
Financing
$26.0M
TLSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLSI vs Medical Device Stocks
Trisalus Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.